Stephen Pakola, M.D.

EVP, Chief Medical OfficeratRegenxbio· In proxies 2022–2025

Pay in FY2025-33% from the year before · Regenxbio stock +86.3% the same year

Stephen Pakola, M.D. was paid $1.8M in FY2025 (Dec), down 33%. Regenxbio stock rose 86.3% that year.

Pay$100 in the stock at the end of FY21 → $44

Pay is from the Summary Compensation Table of each Regenxbio proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

RGNX
RegenxbioPublic company · 4 yr
- EVP, Chief Medical Officer2022 – Present · 4 yrStock in role -79%

Roles come from the proxy statements of each company.

Activity

Pay
Regenxbio EVP, Chief Medical Officer pay fell 33% to $1.8M. The stock rose 86% in FY2025 (Dec).
DEF 14AApr 14, 2026
Pay
Regenxbio EVP, Chief Medical Officer pay fell 18% to $2.7M. The stock fell 57% in FY2024 (Dec).
DEF 14AApr 8, 2025
Pay
Regenxbio EVP, Chief Medical Officer pay rose 78% to $3.3M. The stock fell 21% in FY2023 (Dec).
DEF 14AApr 4, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?